Respiri Ltd
ASX:RSH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.022
0.096
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Respiri Ltd
Common Shares Outstanding
Respiri Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Respiri Ltd
ASX:RSH
|
Common Shares Outstanding
AU$1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Common Shares Outstanding
AU$2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
38%
|
CAGR 10-Years
23%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Common Shares Outstanding
AU$111.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Cochlear Ltd
ASX:COH
|
Common Shares Outstanding
AU$65.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Common Shares Outstanding
AU$835.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Common Shares Outstanding
AU$85.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Respiri Ltd
Glance View
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.
See Also
What is Respiri Ltd's Common Shares Outstanding?
Common Shares Outstanding
1.1B
AUD
Based on the financial report for Jun 30, 2024, Respiri Ltd's Common Shares Outstanding amounts to 1.1B AUD.
What is Respiri Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
15%
Over the last year, the Common Shares Outstanding growth was 36%. The average annual Common Shares Outstanding growth rates for Respiri Ltd have been 17% over the past three years , 17% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
